HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for the treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and endometrial cancer (EMC). It also provides Savolitinib, a potent and selective inhibitor of the mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Additionally, HUTCHMED develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non-pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma. The company also has Fanregratinib, which treats intrahepatic cholangiocarcinoma, and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).
In addition, the company is developing HMPL-760, which is in phase I and II clinical trials to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; and HMPL-506 to treat mixed-lineage leukemia-rearrangement and nucleophosmin 1-mutant AML.
HUTCHMED has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc.
The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
